3/4/2008

Ligand Pharmaceuticals and GlaxoSmithKline announced that the FDA has granted priority review status to Promacta, their treatment for the blood disorder chronic short-term idiopathic thrombocytopenic purpura. Glaxo is in charge of global marketing for the drug, which will be the first medication approved for the condition.

Related Summaries